כל המחקרים
הרשמה בהזמנהPHASE2, PHASE3התערבותי

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

This study is designed to check how safe two different versions of a drug called efgartigimod are over a long period for young people with generalised Myasthenia Gravis (gMG). gMG is a condition that causes muscle weakness. The study will look at efgartigimod given into a vein (IV) and a different form, efgartigimod PH20, given under the skin (SC). All participants will have already taken part in previous studies involving efgartigimod. The aim is to see if these treatments continue to be safe. Participants under 18 can stay in the study until the drug is more widely available. Those 18 and over can stay for up to two years, or until the drug is available commercially, whichever comes first.

במבט חטוף

סטטוס
הרשמה בהזמנה
שלב
PHASE2, PHASE3
נותן חסות
argenx
יעד הרשמה
12
התחל
18 אוגוסט 2022
השלמה משוערת
01 ספט 2029

על מה המחקר הזה?

This study is focused on understanding the long-term safety of a treatment called efgartigimod for young people affected by generalised Myasthenia Gravis, often shortened to gMG. Myasthenia Gravis is a condition that leads to muscle weakness. Researchers want to ensure that this treatment continues to be safe when used over a longer period.

There are two ways efgartigimod has been given in previous studies: one where it's delivered directly into a vein (this is known as IV) and another where a version called efgartigimod PH20 is given as an injection just under the skin (this is known as SC). This current study will continue to give participants the same way they received it before.

All the children and teenagers taking part in this study have already been involved in earlier trials of efgartigimod (named ARGX-113-2006 and ARGX-113-2207). This study is like a follow-up to those. The main aim isn't to see if the drug works, but purely to monitor its safety over a longer timeframe.

נקודות עיקריות

  • This study is about checking the long-term safety of efgartigimod for children and teenagers with gMG.
  • Only those who have been part of earlier efgartigimod studies can join.
  • Participants will continue to receive the efgartigimod treatment they had before.
  • The study aims to observe any effects of the treatment over a longer period.
  • Your doctor and the study team will monitor your health carefully.

מי עשוי להיות זכאי?

To be considered for this study, you must have previously completed one of the earlier efgartigimod studies (ARGX-113-2006 or ARGX-113-2207). This means you reached the end of those studies or you were eligible for another dose but couldn't complete it within the original study's timeframe.

Participants, or their legal guardians if they are under 18, must be able to understand what the study involves and agree to take part. They also need to be willing to follow all the study's instructions. The study is open to both boys and girls between the ages of 2 and 18 years.

You cannot join if you stopped taking part in the previous efgartigimod studies early. Also, pregnant or breastfeeding young women, or those planning to become pregnant, cannot participate. If you have a serious ongoing infection that hasn't cleared up, or another serious medical condition that might make it hard to assess your gMG or put you at risk, you would also not be able to join.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Have I previously completed an efgartigimod study for gMG?
  2. Am I between 2 and 18 years old?
  3. Am I (or my legal guardian) able to understand and follow study instructions?
  4. Am I female and currently not pregnant, breastfeeding, or planning to become pregnant?
  5. Do I have any serious infections or other health conditions that are not well controlled?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you join this study, you will continue to receive the efgartigimod treatment in the same way and at the same dose you did in your previous study. This means either intravenously (into a vein) or subcutaneously (under the skin).

The main purpose is to keep an eye on your long-term safety, so you'll have regular check-ups and assessments by the study team. They will monitor how you are doing and look for any potential side effects.

If you are under 18 years old, you can stay in the study until efgartigimod becomes generally available in your country, or through another program that allows continued access to the drug for gMG. If you are 18 years or older, you can stay in the study for a maximum of two years, or until the drug becomes widely available, whichever happens first.

סיכונים ותועלות פוטנציאליים

The main benefit of taking part in this study is continued access to efgartigimod, which you may have found helpful in previous studies, while its long-term safety is carefully monitored. As with any drug, there are potential risks, and the study team will be looking out for any side effects or unexpected health problems. All participants have the right to leave the study at any time, for any reason, without it affecting their future medical care.

מיקומים (17)

  • Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital
    מיקוד מאומת
    שיקגו, ארצות הברית
  • Atrium Health Neurology Specialty Care
    מיקוד מאומת
    שארלוט, ארצות הברית
  • University of Virginia (UVA) Health - Developmental Pediatrics Clinic
    מיקוד מאומת
    Charlottesville, United States
  • Universitair Ziekenhuis Antwerpen
    מיקוד מאומת
    אדגם, בלגיה
  • UZ Gent
    מיקוד מאומת
    גנט, בלגיה
  • Alberta Childrens Hospital
    מיקוד מאומת
    קלגרי, קנדה
  • Childrens Hospital of Eastern Ontario
    מיקוד מאומת
    אוטווה, קנדה
  • AP-HM- Hôpital de La Timone
    מיקוד מאומת
    מרסיי, צרפת
  • Universitätsklinikum Essen
    מיקוד מאומת
    אסן, גרמניה
  • Hadassah Medical Center- Ein Kerem
    מיקוד מאומת
    ירושלים, ישראל
  • המרכז הרפואי האוניברסיטאי של ליידן
    מיקוד מאומת
    ליידן, הולנד
  • Uniwersyteckie Centrum Kliniczne w Gdansku
    מיקוד מאומת
    Gdansk, Poland

שאלות נפוצות

What is this study testing?

This study is testing the long-term safety of efgartigimod, a treatment for generalised Myasthenia Gravis (gMG), in young people who have taken it before.

מי יכול להצטרף למחקר זה?

This study is for children and teenagers aged 2 to 18 years old who have already completed a previous efgartigimod study for gMG.

What is generalised Myasthenia Gravis (gMG)?

gMG is a condition that causes muscle weakness throughout the body.

כמה זמן אהיה במחקר?

If you're under 18, you can stay until the drug is commercially available. If you're 18 or over, you can stay for up to two years, or until the drug is available.

מה קורה אם אני רוצה להפסיק להשתתף?

You can withdraw from the study at any time, for any reason, without it affecting your medical care.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "Evaluating Long-term Safety of Efgartigimod Administered Int…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.